Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: Effects of short-term Coenzyme Q10 treatment

Morisco, Carmine; Nappi, Antonio; Argenziano, Luigi; Sarno, Domenico; Fonatana, D.; Imbriaco, Massimo; Nicolai, Emanuele; Romanò, Massimo; Rosiello, G.; Cuocolo, Alberto

doi:10.1016/0098-2997(94)90025-6

Cited by 41 publications

(33 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2014, a Cochrane systematic review evaluated seven randomized controlled trials [19,20,29,[33][34][35][36], with a total of 914 patients [10] that compared CoQ10 with placebo in patients with heart failure and demonstrated that there was no effect on total mortality. Thus, although CoQ10 appeared to be safe based on the previous small studies and meta-analyses that appeared underpowered, the ACC/AHA did not recommend CoQ10 in the 2013 guidelines [37].…”

Section: Systematic Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Coenzyme Q10 and Utility in Heart Failure: Just Another Supplement?

Oleck

Ventura²

2016

Curr Heart Fail Rep

View full text Add to dashboard Cite

Heart failure affects 5.1 million people in the USA annually. It accounts for a frequent cause of hospitalizations and disability. Patients with congestive heart failure have lower plasma levels of CoQ10, which is an independent predictor of mortality in this patient population. It has been hypothesized that a deficiency of CoQ10 can play a role in the development and worsening of heart failure, and that oral supplementation can possibly improve symptoms and survival in these patients. Based on previous small studies and meta-analyses, the use of CoQ10 in heart failure suggested an improvement ejection fraction, stroke volume, cardiac output, and cardiac index with CoQ10 supplementation, however most of these small studies appeared to be underpowered to result in any significant data. The results of the recent Q-SYMBIO trial demonstrated an improvement in heart failure symptoms with a significant reduction in major adverse cardiovascular events and mortality.

show abstract

Section: Systematic Reviewmentioning

confidence: 99%

“…Other studies confirmed improvements in cardiac performance with the use of coenzyme Q10 in heart failure and also demonstrated an improvement in quality of life. Some of these studies demonstrated a minimal improvement in survival [17][18][19][20][21][22][23][24][25].…”

Section: Coenzyme Q10mentioning

confidence: 99%

Coenzyme Q10 and Utility in Heart Failure: Just Another Supplement?

Oleck

Ventura²

2016

Curr Heart Fail Rep

View full text Add to dashboard Cite

show abstract

“…Langsjoen and colleagues (1985) demonstrated, in a study of 143 patients, an improvement in stroke volume and EF following CQ10 treatment over a 12-week period. Further studies have confirmed these improvements in cardiac function in HF patients, but these have translated to only minimal improvements in mortality (Morisco, et al, 1994;Munkholm, et al, 1999). Many of these trials however, were underpowered to assess this end-point, and were performed at a time that coincided with the advent of ACEinhibitor and β-blocker therapies, which revolutionized HF treatment and drastically improved survival in their own right.…”

Section: Mitochondrial-targeted Antioxidantsmentioning

confidence: 99%

Cardiac metabolism — A promising therapeutic target for heart failure

Noordali

Loudon

Frenneaux

et al. 2018

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Both heart failure with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF) are associated with high morbidity and mortality. Although many established pharmacological interventions exist for HFrEF, hospitalization and death rates remain high, and for those with HFpEF (approximately half of all heart failure patients), there are no effective therapies. Recently, the role of impaired cardiac energetic status in heart failure has gained increasing recognition with the identification of reduced capacity for both fatty acid and carbohydrate oxidation, impaired function of the electron transport chain, reduced capacity to transfer ATP to the cytosol, and inefficient utilization of the energy produced. These nodes in the genesis of cardiac energetic impairment provide potential therapeutic targets, and there is promising data from recent experimental and early-phase clinical studies evaluating modulators such as carnitine palmitoyltransferase 1 inhibitors, partial fatty acid oxidation inhibitors and mitochondrial-targeted antioxidants.Metabolic modulation may provide significant symptomatic and prognostic benefit for patients suffering from heart failure above and beyond guideline-directed therapy, but further clinical trials are needed.

show abstract

“…Soja i Mortensen [36] dokonali przeglądu 8 podwójnie zaślepionych badań z grupą kontrolną [38][39][40][41][42][43][44][45] i po zastosowaniu suplementacji CoQ 10 odnotowali istotną poprawę w zakresie objętości sobie już wiele dekad. Niektóre wyniki badań wykazały, że suplementacja CoQ 10 przez relatywnie krótki czas może poprawić funkcję skurczową i zmniejszać wymiary komory, podczas gdy inne nie udowodniły korzyści w porównaniu z placebo.…”

Section: Badania Interwencyjne Z Koenzymem Q 10unclassified

“…[3] dokonali przeglądu 12 badań: 10 z nich oceniało frakcję wyrzutową [38,[40][41][42][45][46][47][48][49][50], a 2 -rzut serca [44,46], z dawkowaniem CoQ 10 w zakresie od 60 do 200 mg/dziennie i okresem leczenia od 1 do 6 miesięcy (tab. 1).…”

Section: Jakie Są Konsekwencje Stosowaniaunclassified